Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA OTC Monograph Meetings Guidance Should Be Familiar To Firms Using NDA Pathway

23 Feb 2022

• By Malcolm Spicer

• Source: Alamy

Related Content

'Milestone' Discussions With US FDA On OTC Monograph Proposals Limited To One Meeting

23 Feb 2022

Legislators On OTC Monograph Reform: What Took You So Long?

14 Sep 2017

US OTC Monograph FY2022 Facility Fees Deadline In June At Amount TBD

12 Oct 2021

US FDA Meets Initial Deadlines In OTC Monograph Overhaul While It's Rebuilding The Program

05 Oct 2021

Additional Topics

International United States FDA Guidance Documents OTC Drugs Advertising, Marketing & Sales Commercial Compliance Consumer Distribution Drug Approval Standards Ingredients Legislation Manufacturing Policy Politics Regulation

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.